location:Home >Technical support > References


Posted by star on 2022-02-07 16:50:01 Hits:84
<<  Back
Allan J. C. Bussmann MSc, Camila R. Ferraz PhD, Aline V. A. Lima MD, João G. S. Castro MD, Patrícia D. Ritter MD, Tiago H. Zaninelli MSc, Telma Saraiva-Santos MSc, Waldiceu A. Verri Jr PhD, Sergio M. Borghi PhD
From: Pain practice

Despite the wide variety of Covid-19 symptoms, pain and the related mechanisms underlying unsettled nociceptive status are still under-prioritized. Understanding the complex network of Covid-19-related pain may result in new lines of study. It is unknown whether patients immunological background influences pain in the acute phase of Covid-19, including musculoskeletal pain. Thus, we evaluated the blood levels of selected molecules that are upregulated in SARS-CoV-2 infection and analyzed a possible correlation with pain during Covid-19.
A cohort of 20 hospitalized patients with confirmed diagnoses for Covid-19 were evaluated in the context of pain. Visual analogic scale (VAS) was applied to quantitate pain level. Blood tests were used to determine the systemic levels of cytokines (IL-10 and IL-1β), substance P, and leptin. The data were correlated when appropriate to determine the association between pain-related markers and assessed pain intensity.
Our findings show that systemic levels of IL-10 have strong negative correlation with pain intensity on Covid-19 patients. Additionally, we also show that leptin systemic levels were increased in Covid-19 patients with pain, however, with moderate positive correlation between these events. IL-1β and SP levels did not differ between Covid-19 patients with or without pain. Men reported less pain compared to women. No differences were found between genders in the levels of the molecules evaluated in patients with pain.
IL-10 has been described over the years as an anti-inflammatory and analgesic cytokine. The present data support that low IL-10 levels might contribute to Covid-19-associated pain.
Technical support
Terms and Conditions
Wuhan Abebio Science Co.,Ltd
Room 002,15F-D2,3rd Phase of Software New Park, No.8 Huacheng Avenue, East Lake New-tech Development Zone,Wuhan,China
Email: abebio@abebio.com